Trial Profile
A Multicentre, Multinational, Randomised, Open-labelled, Parallel-group, Active-controlled Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jun 2022
Price :
$35
*
At a glance
- Drugs Somapacitan (Primary) ; Somatropin
- Indications Growth disorders
- Focus Adverse reactions; Registrational
- Acronyms REAL-2
- Sponsors Novo Nordisk
- 16 May 2022 Pooled data from NCT02229851 (REAL 1), NCT02382939 (REAL 2), NCT03075644 ( REAL JP ), published in the European Journal of Endocrinology.
- 01 May 2018 Results published in the European Journal of Endocrinology
- 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society